Showing 4311-4320 of 5627 results for "".
- Vision Health Alliance Launches First Consumer Awareness Campaignhttps://modernod.com/news/vision-health-alliance-launches-first-consumer-awareness-campaign/2479484/Vision Health Alliance, The Vision Council’s new consumer education initiative, announced the launch of its first consumer education movement. The “Let’s Be Clear” campaign debuted last week online across multiple digital and social media channels and features direct, to-the-point me
- AxeroVision Announces Phase 2 Results for Dry Eye Disease Creamhttps://modernod.com/news/axerovision-announces-phase-2-results-for-axr-270-for-treatment-of-dry-eye-disease-associated-with-mgd/2479478/AxeroVision announced positive results from a phase 2 investigational treatment of AXR-270, the company’s novel, proprietary, once-daily glucocorticoid cream, in patients with signs and symptoms of dry eye disease (DED) associated with meibomian gland dysfunction (MGD). I
- Visus Therapeutics to Host Its First Capital Markets Day Tomorrowhttps://modernod.com/news/visus-therapeutics-to-host-its-first-capital-markets-day-tomorrow/2479476/Visus Therapeutics will host its first Capital Markets Day for investors, analysts, and media tomorrow, August 31, 2021, from 10 am to 2 pm ET at Convene, 530 Fifth Avenue at 45th Street in New York City. During the Capital Markets Day, Ben Bergo, co-founder and chief executive
- Texan Eye Enters Partnership with Comprehensive EyeCare Partnershttps://modernod.com/news/texan-eye-enters-partnership-with-comprehensive-eyecare-partners/2479472/Comprehensive EyeCare Partners (CompEye), a vision care practice management organization, has announced a strategic partnership with Texan Eye, an ophthalmic practice in Central Texas with practices in Austin and Cedar Park. Terms of the deal were not disclosed. Texan Eye, led by su
- Pfizer, BioNTech’s COVID-19 Vaccine Bags Full FDA Approvalhttps://modernod.com/news/pfizer-biontechs-covid-19-vaccine-bags-full-fda-approval/2479467/The FDA on Monday approved Pfizer and BioNTech’s BNT162b2, now known in the US as Comirnaty, to prevent COVID-19 in people ages 16 years and older, making it the first coronavirus vaccine to have its emergency-use authorization (EUA) converted into a full approval. “While millions of
- Pfizer, BioNTech’s COVID-19 Vaccine on Brink of Full FDA Approvalhttps://modernod.com/news/pfizer-biontechs-covid-19-vaccine-on-brink-of-full-fda-approval/2479464/According to people familiar with the matter, the FDA is expected to grant full approval to Pfizer and BioNTech’s COVID-19 vaccine BNT162b2 as soon as Monday, The New York Times reported. The sources suggested that the agency was aiming to complete the process by August 20, but was still wo
- Market Scope: Phaco and FLACS Upgrades to Drive Expansion in Cataract Equipment Markethttps://modernod.com/news/market-scope-phaco-and-flacs-upgrades-to-drive-expansion-in-cataract-equipment-market/2479462/A number of market leaders in phaco and femtosecond cataract technology will launch upgraded platforms over the next year, which is expected to increase market penetration for both types of systems and stimulate the replacement of older models. Johnson & Johnson Vision has introduced i
- AAO: Proof of COVID-19 Vaccination Required for All Registrants Attending Annual Meeting in New Orleanshttps://modernod.com/news/aao-proof-of-covid-19-vaccination-required-for-all-registrants-attending-annual-meeting-in-new-orleans/2479461/The American Academy of Ophthalmology’s board of trustees has decided that proof of COVID-19 vaccination will be required for all registrants attending the Academy’s annual meeting in New Orleans. Every AAO 2021 attendee, all Academy staff, exhibitors, and guests will be required to
- Eyeque Announces Series C Closing With More Than $57 Million in Capital Raisedhttps://modernod.com/news/eyeque-announces-series-c-closing-with-more-than-57-million-in-capital-raised/2479459/EyeQue announced that they have closed a Series C round and have raised more than $57 million in capital since the company was founded in 2015. EyeQue aims to bring affordable vision correction with their smartphone vision tests. The company has developed a suite of at-
- Visus Therapeutics Expands Ophthalmic Drug Portfolio With Investigational Therapies for Glaucoma and AMDhttps://modernod.com/news/visus-therapeutics-expands-ophthalmic-drug-portfolio-with-investigational-therapies-for-glaucoma-and-amd/2479457/Visus Therapeutics announced it has entered into a worldwide exclusive licensing agreement with Cella Therapeutics to develop an array of investigational ophthalmic therapies to treat glaucoma and age-related macular degeneration (AMD). The company also announced a worldwide exclusive licensing a